GU Cancers 2019 | Renal cancer highlights from 2019 GU: KEYNOTE-426

Robert Jones, MD, PhD, of the University of Glasgow & Beatson West of Scotland Cancer Centre, Glasgow, UK, pinpoints the Phase III KEYNOTE-426 (NCT02853331) trial as the most impactful renal cancer study presented at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA. Prof. Jones describes that pembrolizumab plus axitinib demonstrated promising progression-free survival (PFS) and overall survival (OS) in metastatic renal cell carcinoma (mRCC) patients, and reports that this combination therapy may well be superior to the current standard of RCC care, sunitinib.